Delving into the Latest Updates on Ampicillin Sodium/Sulbactam Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ampicillin Sodium and Sulbactam Sodium, Ampicillin/Sulbactam, Sulbactam sodium/Ampicillin Sodium

+ [23]

Target

PBPs x β-lactamase

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), β-lactamase inhibitors(Beta Lactamase inhibitors)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesDigestive System Disorders+ [4]

Active Indication

CystitisLung AbscessPeritonitis+ [10]

Inactive Indication

Community Acquired PneumoniaPneumonia, Bacterial

Originator Organization

Pfizer Inc.

Active Organization

Meiji Seika Pharma Co., Ltd.

Ohara Pharmaceutical Co., Ltd.

Pfizer Inc.

+ [4]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (31 Dec 1986),

Bone and joint infectionsCentral Nervous System InfectionsGynecological infection+ [5]

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC24H30N4Na2O9S2

InChIKeyMWBFWOYZSJLWIO-UBWQYZJSSA-N

CAS Registry117060-71-6

CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems. The main resistance mechanisms include carbapenemases, efflux pumps, and changes in the bacterial cell wall.
Current treatments include polymyxins (Colistin, Polymyxin B), which are effective but can lead to resistance, aminoglycosides (Amikacin, Gentamicin), which are limited by resistance, and tetracyclines (Tigecycline, Eravacycline), which are effective against CRAB. Fosfomycin is effective in combination treatments, and combination therapy (e.g., colistin with sulbactam, fosfomycin, or eravacycline) can enhance outcomes.
Previous research shows promise for combination therapies, improving treatment efficacy and reducing mortality. New regimens are being studied to find optimal combinations. Individualized dosing is crucial, considering patient-specific factors like age, weight, and renal function. Adjustments depend on the infection site and comorbidities.
Strict infection control and antimicrobial stewardship programs (ASPs) are essential. ASPs focus on optimizing antibiotic use and reducing resistance through education and surveillance. Future directions include continued research for new drugs or combinations and strategies to overcome resistance and improve treatment efficacy.
Study goals include achieving negative samples after 10 days of therapy, 30-day survival, discharge rates, reduced SOFA scores, and improved clinical and radiological findings. A randomized study will compare colistin combined with fosfomycin, ampicillin/sulbactam, and eravacycline.
In summary, treating CRAB infections is complex, requiring combination therapy, individualized dosing, and strict infection control measures.

Start Date01 Nov 2024

Sponsor / Collaborator-

NCT05922124 / Not yet recruitingPhase 4

Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)

Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.

Start Date30 May 2024

Sponsor / Collaborator

Rambam Health Care Campus

[+2]

NCT06448624 / RecruitingPhase 4IIT

Effect of Single Dose & Intrapocket Prophylactic Antibiotic to Cardiac Implantable Electronic Device-related Infection & Biomarkers

Effect of single dose & intrapocket prophylactic antibiotic to cardiac implantable electronic device-related infection & biomarkers

Start Date01 Apr 2024

Sponsor / Collaborator

Universitas Diponegoro

100 Clinical Results associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

100 Translational Medicine associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

100 Patents (Medical) associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

436

Literatures (Medical) associated with Ampicillin Sodium/Sulbactam Sodium

01 Jan 2024·Indian journal of medical microbiology

Risk factor and resistance profile of colistin resistant Acinetobacter baumannii and Klebsiella pneumoniae

Article

Author: Gupta, Parakriti ; Singhal, Lipika ; Vasesi, Dipanshu ; Gupta, Varsha

PURPOSE:

Antimicrobial resistance is one of the major global health concerns, which is relentless despite multipronged measures. Carbapenems and colistin, drug of choice for multi drug resistant Klebsiella pneumoniae and Acinetobacter species, have also been rendered of less use. This underlines the need to decipher prevalence of colistin resistance comprehensively for formulation of hospital and country-wise antibiogram. We conducted this study to decipher the prevalence of colistin resistance in our tertiary care centre of North India.

MATERIALS AND METHODS:

This was a prospective, case control study conducted over a period of one and half years. All carbapenem resistant Klebsiella pneumoniae and Acinetobacter isolates were included. Kirby-Bauer method of disc diffusion was used for all antibiotics, except colistin for which broth microdilution was performed and interpreted using CLSI guidelines. Demographic details, risk factors and outcome details were recorded. Genotypic characterization was performed using representative strains, for bla_NDM, bla_KPC and bla_OXA-48.

RESULTS:

Of 103 carbapenem resistant isolates, 7 were found to be colistin resistant. Median age was 43 years, with male:female ratio of 1.1:1. 35% isolates were from pus samples, followed by endotracheal aspirate. Colistin resistance was more in ICUs than wards. Presence of indwelling devices was noted as the most common risk factor, followed by previous antibiotic exposure and use of steroids/immunosuppressants. Indwelling devices, steroids/immunosuppressants usage, length of hospital stay, COPD, prior usage of carbapenems, piperacillin-tazobactam and colistin, usage of ampicillin-sulbactam during hospital stay, were statistically significant. Mortality was noted in 4 cases, with statistical difference between control and case arm. The bla_NDM and bla_OXA-48 were noted in 3 and 2 isolates respectively, with absence of bla_KPC.

CONCLUSION:

The present study unravels incidence, risk factors and resistance encoding genes at our centre. This is of immense help in formulation of antibiotic policies and guidance for infection control measures.

01 Dec 2023·International wound journal

Effect of Clindamycin compared with Ampicillin‐Sulbactam as prophylactic antibiotics for wound infections following major surgery for head and neck cancer: A meta‐analysis

Article

Author: Yan, Aihui ; Hu, Yue ; Jiang, Feifei

Abstract:

A meta‐analysis examination was implemented to review the effect of Clindamycin compared with Ampicillin‐Sulbactam as prophylactic antibiotics (PAs) management for surgical site wound infections (SSWIs) following major surgery (MS) for head and neck cancer (H&NC). A comprehensive literature examination till May 2023 was done and 1296 interrelated examinations were reviewed. The six elected examinations, enclosed 4293 personals with MS for H&NC were in the utilized examinations' starting point, 1722 of them were utilizing Clindamycin, and 2571 were utilizing Ampicillin‐Sulbactam. Odds ratio (OR) and 95% confidence intervals (CIs) were utilized to appraise the consequence of Clindamycin compared with Ampicillin‐Sulbactam as PAs management for SSWIs following MS for H&NC by the dichotomous approach and a fixed or random model. Clindamycin had significantly higher SSWI compared with Ampicillin‐Sulbactam (OR, 2.65; 95% CI, 1.40–5.02, p = 0.003) in personals with MS for H&NC. Clindamycin had significantly higher SSWI compared with Ampicillin‐Sulbactam in personals with MS for H&NC. However, caution needs to be taken when interacting with its values because there was a low sample size of some of the chosen examinations and a low number of examinations found for the comparisons in the meta‐analysis.

01 Dec 2023·Canadian journal of microbiology

Effects of short-term exposure to simulated microgravity on the physiology of Bacillus subtilis and multiomic analysis

Article

Author: Guo, Rui ; Su, Xiaolei ; Zhang, Honglei ; Fang, Tingzheng ; Liu, Changting ; Wang, Junfeng ; Fang, Lin ; Wang, Dapeng ; Jiang, Xuege

In our study, Bacillus subtilis was disposed to a simulated microgravity (SMG) environment in high-aspect ratio rotating-wall vessel bioreactors for 14 days, while the control group was disposed to the same bioreactors in a normal gravity (NG) environment for 14 days. The B. subtilis strain exposed to the SMG (labeled BSS) showed an enhanced growth ability, increased biofilm formation ability, increased sensitivity to ampicillin sulbactam and cefotaxime, and some metabolic alterations compared with the B. subtilis strain under NG conditions (labeled BSN) and the original strain of B. subtilis (labeled BSO). The differentially expressed proteins (DEPs) associated with an increased growth rate, such as DNA strand exchange activity, oxidoreductase activity, proton-transporting ATP synthase complex, and biosynthetic process, were significantly upregulated in BSS. The enhanced biofilm formation ability may be related with the DEPs of spore germination and protein processing in BSS, and differentially expressed genes involved in protein localization and peptide secretion were also significantly enriched. The results revealed that SMG may increase the level of related functional proteins by upregulating or downregulating affiliated genes to change physiological characteristics and modulate growth ability, biofilm formation ability ( epsB, epsC, epsN), antibiotic sensitivity ( penP) and metabolism. Our experiment may gives new ideas for the study of space microbiology.

100 Deals associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01CR01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cystitis	JP	Pfizer Japan, Inc.	01 Jul 1994
Lung Abscess	JP	Pfizer Japan, Inc.	01 Jul 1994
Peritonitis	JP	Pfizer Japan, Inc.	01 Jul 1994
Pneumonia	JP	Pfizer Japan, Inc.	01 Jul 1994
Bacterial Infections	CN	Zhongshan Lienpu Pharmaceutical Co., Ltd	01 Jan 1993
Bone and joint infections	US	Pfizer Inc.	31 Dec 1986
Central Nervous System Infections	US	Pfizer Inc.	31 Dec 1986
Gynecological infection	US	Pfizer Inc.	31 Dec 1986
Intraabdominal Infections	US	Pfizer Inc.	31 Dec 1986
Lower Respiratory Tract Infections	US	Pfizer Inc.	31 Dec 1986
Sepsis	US	Pfizer Inc.	31 Dec 1986
Skin and skin structure infections	US	Pfizer Inc.	31 Dec 1986
Urinary Tract Infections	US	Pfizer Inc.	31 Dec 1986

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Community Acquired Pneumonia	Phase 3	JP	Pfizer Inc.	01 Oct 2010
Pneumonia, Bacterial	Phase 3	JP	Pfizer Inc.	01 Oct 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00760006 (CTgov)	Phase 2	Cleft Palate	224	Unasyn (Unasyn Antibiotic Arm)	argrdzkulk(qusljcicej) = rzhchqghkh nscdocjvme (unrewgkklk, cbojejdtft - ilkxlcfkay) View more	-	01 Feb 2018
				saline solution (Saline Placebo Arm)	argrdzkulk(qusljcicej) = fhbfpdvyzr nscdocjvme (unrewgkklk, omflahfrqa - ovvcoupmja) View more
NCT00879190 (CTgov)	Phase 2/3	Chorioamnionitis	92	Unasyn (Unasyn (Ampicillin/Sulbactam))	lcfdncetvz(zbzwejaihr) = mhbhbvwsim ycbyldgymr (tzztsussne, otmvymffad - bdztymjwpe) View more	-	15 Mar 2017
				gentamicin+Ampicillin (Ampicillin/Gentamicin)	lcfdncetvz(zbzwejaihr) = rekwcsztul ycbyldgymr (tzztsussne, iojajhhzcw - yiymsadsdw) View more
ERS2015	Not Applicable	Community Acquired Pneumonia	-	Ampicillin-sulbactam + Macrolide	tcfwbxnlpk(njrdrlpfmt) = ossnobeuec cmxyvsfbmq (tntxzffikn ) View more	Positive	01 Sep 2015
				Fluoroquinolone	tcfwbxnlpk(njrdrlpfmt) = jayhpvpswc cmxyvsfbmq (tntxzffikn ) View more
NCT01189487 (Pubmed \| J Infect Chemother)	Phase 3	Community Acquired Pneumonia	47	Sulbactam/Ampicillin 3 g QID	pcvuotujob(mmsglqtjds) = isqqqjugse fuypvfdjqi (herttdyfnb ) View more	Positive	01 Mar 2015
NCT00630513 (T.E.A. Study, Pubmed \| BMC Gastroenterol)	Phase 4	Intraabdominal Infections	142	Ertapenem	fqchmsqwvb(utmzpqmwwh) = ytdmvkvkok lmoisdnzli (iqgmvnitqa )	Positive	30 Apr 2013
NCT00356148 (Pubmed \| Ann Surg)	Phase 4	Breast Cancer	369	prophylactic antibiotic administration (Prophylaxis group)	mwxpxdzfhc(mjxhwnezuo) = scfifliycz utttzuorgv (cfozvbwuqr ) View more	Positive	01 Jan 2013
				prophylactic antibiotic administration (Control group)	mwxpxdzfhc(mjxhwnezuo) = mukoohszom utttzuorgv (cfozvbwuqr ) View more
NCT00368537 (CTgov)	Phase 4	Skin Diseases, Bacterial \| Skin and skin structure infections \| Soft Tissue Infections	550	Tigecycline (Tigecycline)	pjxuitszri(vgoxqpapcj) = fpmudbcjkj gmvvcdjccn (rnrxwthdfi, wbjudfsucs - tiuzzjlirj) View more	-	09 Aug 2012
				Ampicillin-Sulbactam+Amoxicillin-Clavulanate (Ampicillin-Sulbactam or Amoxicillin-Clavulanate)	pjxuitszri(vgoxqpapcj) = clpyoqpdgo gmvvcdjccn (rnrxwthdfi, ngwrjegwpv - ouifjpshqv) View more
NCT01189487 (CTgov)	Phase 3	Pneumonia, Bacterial \| Community Acquired Pneumonia	47	ampicillin sodium/sulbactam sodium	norfvhfgye(ucwwmfgbpf) = frttysihxm hoetnsatne (fkoelywppj, cvpwjhbyth - uddqbadzkr) View more	-	18 May 2012
ASN2011	Not Applicable	Acute Kidney Injury	12	Ampicillin/Sulbactam 2g/1g	cznmakquqs(jqopkmbvqh) = sutjkudtli lhxlfpbkth (ddbvckjypx, 7.7)	Positive	08 Nov 2011
NCT01138852 (Pubmed \| BMC Infect Dis)	Phase 4	-	176	Ampicillin-sulbactam	irglztsdtq(emxizukfkp) = zremnrjlfx nxbrelmgrn (tzkfvhhxml )	-	30 Nov 2010
				Cefuroxime	irglztsdtq(emxizukfkp) = ydylaqylcg nxbrelmgrn (tzkfvhhxml )